Nifty
:
25910.05
Sensex
:
84673.02
-103.40 (-0.40%)
-277.93 (-0.33%)
Nifty
Sensex
:
:
25910.05
84673.02
-103.40 (-0.40%)
-277.93 (-0.33%)

Mankind Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
59/99

BSE: 543904 | NSE: MANKIND

NSE BSE
Not traded in the last 30 days
  • Open
  • High
  • Low
  • Previous Close
  •  N/A
  •  N/A
  •  N/A
  •  N/A
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  N/A
  •  N/A
  •  N/A
  •  N/A

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 92,658.09
  • 52.92
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,00,403.74
  • N/A
  • 6.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.67%
  • 1.07%
  • 1.36%
  • FII
  • DII
  • Others
  • 12.83%
  • 9.55%
  • 2.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 14.46
  • 11.74

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.87
  • 9.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.44
  • 15.72

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Earnings Forecasts:

(Updated: 08-11-2025)
Description
2024
2025
2026
2027
Adj EPS
48.26
50.98
65.43
80.16
P/E Ratio
46.56
44.08
34.34
28.03
Revenue
12207.4
14740.7
16460.6
18331.4
EBITDA
3554.72
3782.75
4419.6
5065.2
Net Income
1990.96
2101.7
2702.64
3288.72
ROA
10.02
7.56
9.59
11.73
P/B Ratio
6.47
5.64
4.89
4.24
ROE
16.8
13.52
15.16
16.02
FCFF
1913.15
2541.25
2912.98
3384.32
FCFF Yield
1.78
2.37
2.71
3.15
Net Debt
6266.11
3810.05
1172.14
-1957.93
BVPS
347.39
398.31
459.95
530.1

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
3,697.16
3,061.43
20.77%
3,570.35
2,867.85
24.50%
3,079.37
2,422.24
27.13%
3,230.00
2,606.95
23.90%
Expenses
2,775.83
2,214.24
25.36%
2,723.58
2,196.29
24.01%
2,396.18
1,835.94
30.52%
2,400.20
2,000.45
19.98%
EBITDA
921.33
847.19
8.75%
846.77
671.56
26.09%
683.19
586.30
16.53%
829.80
606.50
36.82%
EBIDTM
24.92%
27.67%
23.72%
23.42%
22.19%
24.20%
25.69%
23.26%
Other Income
91.87
109.06
-15.76%
79.88
99.40
-19.64%
251.33
92.15
172.74%
77.32
70.13
10.25%
Interest
169.68
7.10
2,289.86%
170.65
10.84
1,474.26%
190.54
9.17
1,977.86%
220.93
9.19
2,304.03%
Depreciation
221.82
100.49
120.74%
218.68
102.69
112.95%
230.87
99.78
131.38%
192.30
109.72
75.26%
PBT
621.70
848.66
-26.74%
537.32
657.43
-18.27%
513.11
569.50
-9.90%
493.89
557.72
-11.44%
Tax
103.84
189.98
-45.34%
95.87
122.86
-21.97%
86.44
94.99
-9.00%
112.81
102.51
10.05%
PAT
517.86
658.68
-21.38%
441.45
534.57
-17.42%
426.67
474.51
-10.08%
381.08
455.21
-16.28%
PATM
14.01%
21.52%
12.36%
18.64%
13.86%
19.59%
11.80%
17.46%
EPS
12.39
16.31
-24.03%
10.62
13.39
-20.69%
10.20
11.76
-13.27%
9.22
11.33
-18.62%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
13,576.88
12,207.44
10,260.44
8,749.43
7,781.56
6,214.43
Net Sales Growth
23.89%
18.98%
17.27%
12.44%
25.22%
 
Cost Of Goods Sold
3,926.36
3,489.04
3,198.47
2,913.64
2,421.73
1,780.60
Gross Profit
9,650.52
8,718.40
7,061.97
5,835.79
5,359.83
4,433.82
GP Margin
71.08%
71.42%
68.83%
66.70%
68.88%
71.35%
Total Expenditure
10,295.79
9,186.97
7,745.27
6,847.50
5,791.01
4,565.32
Power & Fuel Cost
-
149.49
125.16
108.96
103.13
82.53
% Of Sales
-
1.22%
1.22%
1.25%
1.33%
1.33%
Employee Cost
-
2,692.37
2,260.60
1,918.47
1,620.59
1,415.78
% Of Sales
-
22.06%
22.03%
21.93%
20.83%
22.78%
Manufacturing Exp.
-
216.03
172.71
150.57
189.81
140.14
% Of Sales
-
1.77%
1.68%
1.72%
2.44%
2.26%
General & Admin Exp.
-
1,314.02
939.49
1,000.80
626.47
451.75
% Of Sales
-
10.76%
9.16%
11.44%
8.05%
7.27%
Selling & Distn. Exp.
-
1,164.71
924.26
638.11
708.17
587.73
% Of Sales
-
9.54%
9.01%
7.29%
9.10%
9.46%
Miscellaneous Exp.
-
161.31
124.58
116.96
121.10
106.78
% Of Sales
-
1.32%
1.21%
1.34%
1.56%
1.72%
EBITDA
3,281.09
3,020.47
2,515.17
1,901.93
1,990.55
1,649.11
EBITDA Margin
24.17%
24.74%
24.51%
21.74%
25.58%
26.54%
Other Income
500.40
536.79
280.22
128.57
196.03
170.95
Interest
751.80
431.95
34.24
45.76
59.80
21.16
Depreciation
863.67
621.22
378.42
325.92
166.62
118.97
PBT
2,166.02
2,504.09
2,382.73
1,658.81
1,960.15
1,679.93
Tax
398.96
509.74
457.15
361.56
521.64
398.58
Tax Rate
18.42%
20.36%
19.19%
21.80%
26.61%
23.73%
PAT
1,767.06
1,986.43
1,911.92
1,281.86
1,433.48
1,265.42
PAT before Minority Interest
1,743.92
2,006.59
1,940.79
1,309.68
1,452.96
1,293.03
Minority Interest
-23.14
-20.16
-28.87
-27.82
-19.48
-27.61
PAT Margin
13.02%
16.27%
18.63%
14.65%
18.42%
20.36%
PAT Growth
-16.76%
3.90%
49.15%
-10.58%
13.28%
 
EPS
42.81
48.12
46.32
31.05
34.73
30.65

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
14,332.39
9,363.09
7,435.22
6,155.23
4,722.00
Share Capital
41.26
40.06
40.06
40.06
40.06
Total Reserves
14,247.46
9,299.78
7,395.10
6,115.17
4,681.94
Non-Current Liabilities
7,419.90
187.34
199.24
168.68
107.33
Secured Loans
5,077.83
24.87
23.15
48.94
57.42
Unsecured Loans
448.36
0.00
0.00
0.25
0.25
Long Term Provisions
155.06
123.12
97.89
80.00
72.24
Current Liabilities
5,663.56
2,119.73
1,863.14
2,623.46
1,353.40
Trade Payables
1,133.40
777.06
1,008.18
1,076.40
666.97
Other Current Liabilities
1,335.07
755.50
386.05
472.89
282.77
Short Term Borrowings
2,513.14
151.48
115.02
794.59
158.35
Short Term Provisions
681.95
435.69
353.89
279.59
245.30
Total Liabilities
27,651.64
11,882.86
9,685.67
9,108.45
6,323.62
Net Block
19,004.48
4,539.95
4,245.28
3,582.77
1,658.94
Gross Block
20,916.96
5,909.74
5,233.03
4,246.54
2,160.04
Accumulated Depreciation
1,912.48
1,369.79
987.75
663.78
501.10
Non Current Assets
20,663.37
5,314.64
5,357.80
4,701.63
2,416.98
Capital Work in Progress
825.67
281.80
550.15
701.47
371.95
Non Current Investment
351.09
309.81
270.95
235.01
205.80
Long Term Loans & Adv.
293.08
163.97
187.54
163.88
158.07
Other Non Current Assets
189.00
13.79
98.51
13.09
16.72
Current Assets
6,985.57
6,565.52
4,324.56
4,403.84
3,906.64
Current Investments
1,690.84
2,258.11
1,075.47
874.46
1,306.17
Inventories
2,093.71
1,553.46
1,498.46
1,760.24
1,183.54
Sundry Debtors
1,538.34
848.28
576.42
388.17
330.61
Cash & Bank
554.50
708.10
453.20
405.94
700.74
Other Current Assets
1,108.18
104.10
64.29
170.74
385.57
Short Term Loans & Adv.
1,010.76
1,093.47
656.71
804.29
275.79
Net Current Assets
1,322.01
4,445.79
2,461.42
1,780.37
2,553.24
Total Assets
27,648.94
11,880.16
9,682.36
9,105.47
6,323.62

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
2,413.38
2,152.44
1,813.30
919.78
1,137.24
PBT
2,524.78
2,399.35
1,671.24
1,974.60
1,691.61
Adjustment
601.77
212.19
298.43
30.81
-5.66
Changes in Working Capital
-146.42
-17.57
166.73
-586.12
-94.63
Cash after chg. in Working capital
2,980.13
2,593.97
2,136.40
1,419.29
1,591.32
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-566.75
-441.53
-323.10
-499.51
-454.07
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-12,682.95
-2,081.69
-1,054.13
-1,369.14
-1,222.21
Net Fixed Assets
-270.57
-517.31
-591.49
-2,286.21
Net Investments
-12,468.02
-1,113.13
-576.36
-128.98
Others
55.64
-451.25
113.72
1,046.05
Cash from Financing Activity
10,232.56
5.27
-739.73
604.62
-7.81
Net Cash Inflow / Outflow
-37.01
76.02
19.44
155.26
-92.78
Opening Cash & Equivalents
382.01
304.82
283.06
127.33
219.73
Closing Cash & Equivalent
403.88
382.01
304.82
283.06
127.33

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
346.31
233.15
185.61
153.65
117.88
ROA
10.15%
18.00%
13.94%
18.83%
22.79%
ROE
16.98%
23.14%
19.27%
26.72%
31.51%
ROCE
18.32%
28.35%
23.49%
33.96%
39.97%
Fixed Asset Turnover
0.95
1.92
1.92
2.52
3.00
Receivable days
34.35
24.35
19.33
16.25
25.31
Inventory Days
52.50
52.16
65.31
66.57
61.16
Payable days
99.93
101.86
130.57
131.38
144.73
Cash Conversion Cycle
-13.08
-25.35
-45.92
-48.56
-58.26
Total Debt/Equity
0.58
0.02
0.02
0.14
0.05
Interest Cover
6.83
71.03
37.52
34.02
80.96

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Mankind Pharma reports 21% fall in Q2 consolidated net profit
    7th Nov 2025, 15:28 PM

    The consolidated total income of the company increased by 19.51% at Rs 3,789.03 crore for Q2FY26

    Read More
  • Mankind Pharma - Quarterly Results
    7th Nov 2025, 00:00 AM

    Read More
  • Mankind Pharma inks pact to acquire Women Health Rx Portfolio of BSV
    13th Oct 2025, 15:00 PM

    The company will acquire the business at a consideration of Rs 797 crore

    Read More
  • Mankind Pharma incorporates wholly owned subsidiary in Russia
    19th Aug 2025, 16:58 PM

    Mankind Pharma LLC shall carry out the business of distribution of pharmaceutical products of Bharat Serums and Vaccines

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.